Indigenously Fecal Incontinence System Launched in New Delhi
Aimed to train the next generation of medical technology innovators in India to develop innovative and affordable medical devices to augment unmet clinical needs of India, an innovative medical device has been developed under Department of Biotechnology (DBT), Ministry of Science & Technology supported Bio design Programme by M/s. Consure Medical, New Delhi.
A spin-off from the Program Bio design is a Med-Tech innovation Program of DBT. This Program is implemented at AIIMS and IIT, Delhi in collaboration with International partners such as Stanford University, USA, Queensland University of Technology, Australia and Tottori University and Japan.
Fecal incontinence (FI) is a medical condition marked by inability to control one’s bowel movements, causing stool (feces) to leak unexpectedly from the rectum. It affects nearly 100 million bed ridden patients worldwide. Furthermore, about 50% of the psychiatric ward patients have FI due to long-term neurological diseases. Absorbent pads and fecal drainage catheters are the only available solutions for this condition a need for a better solution was felt by the team.
M/s. Consure Medical has been founded in 2012 by Mr. Nishith Chasmawala and Mr. Amit Sharma, the inventors of the technology. This Company has developed this novel technology ‘Fecal Incontinence Management System-Qora’ to address the clinical and economical implications of fecal incontinence by expanding indications for use, reducing skill level required to use a device, and introducing a new level of care for patients outside the ICU. The product was clinically validated at AIIMS, New Delhi. After nearly two years of intense development, the Consure Medical has developed the QoraTM Stool Management Kit, the world’s first FDA 510(k) approved indwelling fecal drainage device for the management of fecal incontinence that can be used across a continuum of care facilities from ICUs to nursing homes. In select markets like India, caretakers of bedridden patients at home can use the device.
The intellectual property for the company’s core QoraTM technology under DBT’s ownership has been granted in key markets, including US, EU, Canada, Singapore, Australia, and Japan. As a result of its elegant and versatile design, the QoraTM technology has the potential to expand globally and benefit more than 100 million fecal incontinent patients each year.